CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Mineralys Therapeutics, Inc. (MLYS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Mineralys Therapeutics, Inc. (MLYS)

Pharmaceutical Preparations · market cap $2.5B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01
Regulatory
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Mineralys Therapeutics (MLYS) is a 51-employee clinical-stage company with a ~$1.82B market cap (~$20.56/share). Its lead asset, lorundrostat, has a PDUFA date of 2026-12-22 for hypertension in combination with other antihypertensive drugs, and a Phase 3 program in obstructive sleep apnea. Our data shows cash of $138.3M and a 12.7-month runway, so the setup is a binary regulatory event for a company that has not yet shown commercial revenue in our data.
The catalyst path
  • 2026-12-01Regulatoryimp 3/10
  • 2026-12-22PDUFA · Lorundrostatimp 6/10
Pipeline
AssetPhaseIndication
lorundrostat Dose 1Phase 3Hypertension
MLS-101 (Part I)Phase 2Hypertension, Renal
LorundrostatPhase 3Obstructive Sleep Apnea
lorundrostat Dose 2Phase 3Hypertension
MLS-101 (Part II)Phase 2Hypertension, Renal
Price & technical context
3-month
-43.9%
6-month
-43.4%
12-month
-66.3%
52-wk range
$14.93–$44.26
vs 50-day MA
-33.3%
vs 200-day MA
-42.7%
Realized vol
61.3%
Max drawdown
-68.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MLYS (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.